Chemotherapy-induced Febrile Neutropenia
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Febrile Neutropenia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-02-24EMA Authorised: Vivlipeg (pegfilgrastim) — Biosimilar Collaborations Ireland Limited
The EMA authorised Vivlipeg, a biosimilar pegfilgrastim. The product is indicated for neutropenia and related febrile neutropenia in cancer …
-
EMA approval · 2025-12-08EMA Authorised: Neulasta (pegfilgrastim) — Amgen Europe B.V.
EMA authorised Neulasta (pegfilgrastim) by Amgen Europe B.V. to reduce the risk of neutropenia, febrile neutropenia, and chemotherapy-induce…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy [Phase 3]
Phase 3 clinical trial evaluating a PEG-G-CSF injection to prevent chemotherapy-induced neutropenia, with status listed as active but not re…
-
CLINICAL_TRIALS research · 2024-09-27Clinical Trial Update: Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints [Phase 4]
Phase 4 clinical trial evaluating the efficacy and safety of QL0605 injections given at different timepoints for chemotherapy-induced febril…
-
CLINICAL_TRIALS trial_result · 2022-02-14Clinical Trial Update: Efficacy and Safety Study With MYL-1401H and Neulasta [Phase 3]
Phase 3 trial update evaluating efficacy and safety of MYL-1401H with Neulasta in breast cancer patients with chemotherapy-induced febrile n…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-03-13Clinical Trial Update: Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients [Phase 4]
Phase 4 trial updating timing of granulocyte colony-stimulating factor (G-CSF) after chemotherapy in pediatric patients to assess outcomes.
-
CLINICAL_TRIALS trial_result · 2019-02-11Clinical Trial Update: Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
Non-interventional study evaluating home administration of the filgrastim biosimilar Nivestim for primary prophylaxis of chemotherapy-induce…